• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

低剂量西地那非治疗 1 周可降低胆汁性肝硬化大鼠肝内阻力:与 NO 生物利用度的关系。

Administration of a low dose of sildenafil for 1 week decreases intrahepatic resistance in rats with biliary cirrhosis: the role of NO bioavailability.

机构信息

Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.

出版信息

Clin Sci (Lond). 2010 Apr 7;119(1):45-55. doi: 10.1042/CS20090601.

DOI:10.1042/CS20090601
PMID:20132096
Abstract

Increasing NO bioavailability improves hepatic endothelial dysfunction, which ameliorates intrahepatic resistance and portal hypertension. Acute administration of sildenafil increases hepatic production of NO with a reduction in hepatic sinusoid resistance in cirrhotic patients and enhances the vasorelaxation response to NO in cirrhotic rat livers. However, the mechanisms were still unclear. Therefore, our present study aims to evaluate the effects and mechanisms of administration of sildenafil for 1 week on the hepatic microcirculation of cirrhotic rats. Cirrhosis was induced by bile duct ligation with sham-operated rats serving as normal controls. Intrahepatic resistance was evaluated by in situ liver perfusion. Expression of phospho-eNOS (endothelial NO synthase), iNOS (inducible NO synthase), phospho-Akt, PDE-5 (phosphodiesterase-5) and sGC (soluble guanylate cyclase) were determined by Western blot analysis. Biosynthesis of BH4 (tetrahydrobiopterin) and GTPCH-I (GTP cyclohydrolase I) activity were examined by HPLC. Intravital microscopy was used to observe the direct change in hepatic microcirculation. In cirrhotic rat livers, sildenafil treatment increased hepatic sinusoid volumetric flow, NO bioavailability, BH4, GTPCH-I activity, and the protein expression of phospho-Akt, phospho-eNOS and sGC. These events were associated with reduced protein expression of PDE-5, portal perfusion pressure and portal vein pressure. In contrast, sham rats did not produce any significant change in these measurements. In conclusion, sildenafil treatment improves endothelial dysfunction by augmenting NO bioavailability in the hepatic microcirculation.

摘要

增加 NO 的生物利用度可改善肝内皮功能障碍,从而减轻肝内阻力和门静脉高压。在肝硬化患者中,急性给予西地那非可增加肝内 NO 的产生,减少肝窦阻力,并增强肝硬化大鼠肝脏对 NO 的血管舒张反应。然而,其机制仍不清楚。因此,本研究旨在评估西地那非治疗 1 周对肝硬化大鼠肝微循环的影响及其机制。通过胆管结扎诱导肝硬化,假手术大鼠作为正常对照。通过原位肝灌注评估肝内阻力。通过 Western blot 分析测定磷酸化 eNOS(内皮型一氧化氮合酶)、iNOS(诱导型一氧化氮合酶)、磷酸化 Akt、PDE-5(磷酸二酯酶-5)和 sGC(可溶性鸟苷酸环化酶)的表达。通过 HPLC 检测 BH4(四氢生物蝶呤)和 GTPCH-I(GTP 环水解酶 I)的生物合成。使用活体显微镜观察肝微循环的直接变化。在肝硬化大鼠肝脏中,西地那非治疗可增加肝窦容积流量、NO 生物利用度、BH4、GTPCH-I 活性以及磷酸化 Akt、磷酸化 eNOS 和 sGC 的蛋白表达。这些变化与 PDE-5 蛋白表达降低、门静脉灌注压和门静脉压降低有关。相比之下,假手术大鼠在这些测量中没有产生任何显著变化。总之,西地那非治疗通过增加肝内微循环中 NO 的生物利用度改善内皮功能障碍。

相似文献

1
Administration of a low dose of sildenafil for 1 week decreases intrahepatic resistance in rats with biliary cirrhosis: the role of NO bioavailability.低剂量西地那非治疗 1 周可降低胆汁性肝硬化大鼠肝内阻力:与 NO 生物利用度的关系。
Clin Sci (Lond). 2010 Apr 7;119(1):45-55. doi: 10.1042/CS20090601.
2
Chronic administration of ursodeoxycholic acid decreases portal pressure in rats with biliary cirrhosis.长期给予熊去氧胆酸可降低胆汁性肝硬化大鼠的门静脉压力。
Clin Sci (Lond). 2009 Jan;116(1):71-9. doi: 10.1042/CS20080075.
3
Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis support for a risk in cirrhotic patients.西地那非在肝硬化体内动物模型中的全身和内脏血流动力学效应:对肝硬化患者风险的支持
Liver Int. 2004 Feb;24(1):63-8. doi: 10.1111/j.1478-3231.2004.00892.x.
4
Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.氟比洛芬酯,一种释放一氧化氮的环氧化酶抑制剂,可改善大鼠肝硬化门静脉高压症。
Gastroenterology. 2007 Feb;132(2):709-19. doi: 10.1053/j.gastro.2006.12.041. Epub 2006 Dec 20.
5
Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis.RhoA和Rho激酶信号通路在肝内的上调导致继发性胆汁性肝硬化大鼠肝血管阻力增加。
Gut. 2006 Sep;55(9):1296-305. doi: 10.1136/gut.2005.081059. Epub 2006 Feb 21.
6
Vasopressin response and shunting modulation in cirrhotic rats by chronic nitric oxide inhibition.慢性一氧化氮抑制对肝硬化大鼠血管加压素反应及分流调节的影响
J Gastroenterol Hepatol. 2008 Jul;23(7 Pt 2):e265-9. doi: 10.1111/j.1440-1746.2007.05122.x. Epub 2007 Aug 30.
7
Liposome-mediated gene transfer of endothelial nitric oxide synthase to cirrhotic rat liver decreases intrahepatic vascular resistance.脂质体介导的内皮型一氧化氮合酶基因转移至肝硬化大鼠肝脏可降低肝内血管阻力。
J Gastroenterol Hepatol. 2008 Aug;23(8 Pt 2):e487-93. doi: 10.1111/j.1440-1746.2007.05244.x. Epub 2007 Dec 7.
8
Chronic inhibition of nitric-oxide synthase induces hypertension and erectile dysfunction in the rat that is not reversed by sildenafil.慢性抑制一氧化氮合酶会导致大鼠高血压和勃起功能障碍,而西地那非不能逆转这种情况。
BJU Int. 2010 Jul;106(1):78-83. doi: 10.1111/j.1464-410X.2009.09104.x. Epub 2009 Dec 11.
9
The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis.
Hepatology. 2006 Jul;44(1):44-52. doi: 10.1002/hep.21228.
10
Effects of N-acetylcysteine administration in hepatic microcirculation of rats with biliary cirrhosis.N-乙酰半胱氨酸给药对胆汁性肝硬化大鼠肝微循环的影响。
J Hepatol. 2008 Jul;49(1):25-33. doi: 10.1016/j.jhep.2008.02.012. Epub 2008 Mar 14.

引用本文的文献

1
From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension.从病理生理学到临床实践:门静脉高压症不断发展的药物治疗、临床并发症及药物遗传学考量
Metabolites. 2025 Jan 23;15(2):72. doi: 10.3390/metabo15020072.
2
Close Relationship between Systemic Arterial and Portal Venous Pressure in an Animal Model with Healthy Liver.健康肝脏动物模型中系统性动脉压与门静脉压的密切关系。
Int J Mol Sci. 2023 Jun 9;24(12):9963. doi: 10.3390/ijms24129963.
3
The Hepatic Sinusoid in Chronic Liver Disease: The Optimal Milieu for Cancer.
慢性肝病中的肝血窦:癌症的最佳环境。
Cancers (Basel). 2021 Nov 15;13(22):5719. doi: 10.3390/cancers13225719.
4
Cyclic GMP in Liver Cirrhosis-Role in Pathophysiology of Portal Hypertension and Therapeutic Implications.环鸟苷酸在肝硬化中的作用——门脉高压病理生理学中的作用和治疗意义。
Int J Mol Sci. 2021 Sep 26;22(19):10372. doi: 10.3390/ijms221910372.
5
Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension.肝脏中的磷酸二酯酶作为肝硬化门脉高压的潜在治疗靶点。
Int J Mol Sci. 2020 Aug 28;21(17):6223. doi: 10.3390/ijms21176223.
6
Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats.双重血管紧张素受体和中性肽链内切酶抑制剂改善门静脉高压大鼠的门静脉高压
Pharmaceutics. 2020 Apr 2;12(4):320. doi: 10.3390/pharmaceutics12040320.
7
Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.实验性肝硬化中环鸟苷酸-一氧化氮通路分析表明磷酸二酯酶-5 可能是治疗门脉高压的靶点。
World J Gastroenterol. 2018 Oct 14;24(38):4356-4368. doi: 10.3748/wjg.v24.i38.4356.
8
Dabigatran Reduces Liver Fibrosis in Thioacetamide-Injured Rats.达比加群酯可减少硫代乙酰胺致肝纤维化大鼠的肝纤维化。
Dig Dis Sci. 2019 Jan;64(1):102-112. doi: 10.1007/s10620-018-5311-1. Epub 2018 Oct 4.
9
Treatment Barriers in Portopulmonary Hypertension.门脉高压性肺高血压的治疗障碍。
Hepatology. 2019 Jan;69(1):431-443. doi: 10.1002/hep.30197. Epub 2018 Dec 18.
10
The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats.可溶性鸟苷酸环化酶刺激剂利奥西呱可降低肝硬化大鼠的纤维化和门静脉压力。
Sci Rep. 2018 Jun 19;8(1):9372. doi: 10.1038/s41598-018-27656-y.